4月24日,亚盛医药-B(06855)发布公告,宣布其两项研究成果入选2025年美国临床肿瘤学会(ASCO)年会。
细胞凋亡管线重点品种Bcl-2选择性抑制剂Lisaftoclax(APG-2575)联合治疗髓系恶性肿瘤患者的Ib/II期研究最新进展将以口头报告的形式展示。该研究的摘要编号为6505,报告时间定于2025年6月2日下午15:00至18:00(美国中部时间)。
MDM2-p53抑制剂Alrizomadlin(APG-115)的II期临床研究也将进行壁报展示,摘要编号为6102,报告时间为2025年6月2日上午9:00至中午12:00(美国中部时间)。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.